ProMetic Life Sciences Company Profile (TSE:PLI)

About ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences logoPrometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:PLI
  • CUSIP: N/A
  • Web: prometic.com/
Capitalization:
  • Market Cap: C$1.07 billion
  • Outstanding Shares: 668,706,000
Average Prices:
  • 50 Day Moving Avg: C$1.79
  • 200 Day Moving Avg: C$2.09
  • 52 Week Range: C$1.45 - C$3.24
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: C$16.01 million
  • Price / Sales: 66.83
  • Book Value: C$0.19 per share
  • Price / Book: 8.42
Profitability:
  • EBIDTA: ($111,730,000.00)
  • Net Margins: -598.71%
  • Return on Equity: -81.47%
  • Return on Assets: -45.16%
Misc:
  • Average Volume: 704,748 shs.
  • Short Ratio: 13.79
 

Frequently Asked Questions for ProMetic Life Sciences (TSE:PLI)

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Tornton Stock Exchange (TSX) under the ticker symbol "PLI."

Where is ProMetic Life Sciences' stock going? Where will ProMetic Life Sciences' stock price be in 2017?

5 brokers have issued twelve-month price targets for ProMetic Life Sciences' shares. Their forecasts range from C$4.00 to C$4.85. On average, they expect ProMetic Life Sciences' share price to reach C$4.37 in the next year. View Analyst Ratings for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:

  • Simon Geoffrey Best, Independent Chairman of the Board
  • Pierre Laurin Ph.D., President, Chief Executive Officer, Non-Independent Director
  • Gregory L. Weaver, Chief Financial Officer
  • Bruce Pritchard, Chief Operating Officer
  • John Moran M.D., Chief Medical Officer, Director
  • Patrick Sartore, Chief Legal Officer and Corporate Secretary
  • Stefan Clulow, Non-Independent Director
  • Kenneth H. Galbraith, Director
  • Charles N. Kenworthy, Non-Independent Director
  • Bruce J. Wendel, Non-Independent Director

How do I buy ProMetic Life Sciences stock?

Shares of ProMetic Life Sciences and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of ProMetic Life Sciences stock can currently be purchased for approximately C$1.60.


MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)
Community Ranking:  4.0 out of 5 (   )
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ProMetic Life Sciences (TSE:PLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: C$4.37

Analysts' Ratings History for ProMetic Life Sciences (TSE:PLI)
Show:
DateFirmActionRatingPrice TargetDetails
7/7/2017ScotiabankLower Price TargetOutperformC$4.75 -> C$4.00View Rating Details
6/19/2017Canaccord GenuityLower Price TargetBuyC$4.75 -> C$4.50View Rating Details
5/24/2017Royal Bank Of CanadaReiterated RatingOutperformView Rating Details
4/3/2017TD SecuritiesSet Price TargetSpeculative BuyC$4.50View Rating Details
10/13/2016Bloom BurtonReiterated RatingHoldView Rating Details
8/25/2016CIBCLower Price TargetC$5.00 -> C$4.85View Rating Details
5/26/2016National Bank FinancialReiterated RatingOutperformC$4.90View Rating Details
3/28/2016Paradigm CapitalBoost Price TargetBuyC$2.90 -> C$3.30View Rating Details
1/29/2016Panmure GordonBoost Price TargetBuyC$6.70View Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for ProMetic Life Sciences (TSE:PLI)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ProMetic Life Sciences (TSE:PLI)
Current Year EPS Consensus Estimate: $-0.15 EPS

Dividends

Dividend History for ProMetic Life Sciences (TSE:PLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ProMetic Life Sciences (TSE:PLI)
Insider Trades by Quarter for ProMetic Life Sciences (TSE:PLI)
Insider Trades by Quarter for ProMetic Life Sciences (TSE:PLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/10/2017Louise MénardDirectorSell82,202C$1.60C$131,523.20
6/1/2017Martin LeclercInsiderBuy7,000C$2.04C$14,280.00
5/30/2017Bruce WendelDirectorBuy2,474C$1.52C$3,760.48
5/25/2017Martin LeclercInsiderBuy8,950C$2.03C$18,168.50
5/18/2017Simon Geoffrey BestDirectorBuy10,000C$2.06C$20,600.00
4/19/2017Andrew Trevor BishopDirectorBuy10,000C$2.09C$20,900.00
4/7/2017Bruce PritchardInsiderBuy15,300C$2.18C$33,354.00
2/6/2017Bruce WendelDirectorBuy1,210C$1.66C$2,008.60
10/7/2016Simon Geoffrey BestDirectorBuy2,750C$2.93C$8,057.50
4/6/2016Bruce PritchardInsiderBuy8,800C$3.19C$28,050.88
4/5/2016Bruce WendelDirectorBuy35,200C$2.45C$86,387.84
1/21/2016Raymond Manuel HakimDirectorBuy10,000C$2.77C$27,700.00
1/20/2016Pierre LaurinDirectorBuy2,000C$2.62C$5,240.00
1/19/2016Gregory WeaverInsiderBuy25,000C$2.78C$69,500.00
1/12/2016Louise M�NardDirectorBuy1,867C$2.94C$5,488.98
12/31/2015Kurt Stefan Victor ClulowDirectorBuy273,800C$3.42C$937,737.62
12/29/2015Kurt Stefan Victor ClulowDirectorBuy232,700C$3.22C$749,875.75
12/21/2015Kurt Stefan Victor ClulowDirectorBuy439,500C$3.16C$1,388,160.75
12/4/2015Gregory WeaverInsiderBuy5,000C$2.14C$10,706.50
12/3/2015Gregory WeaverInsiderBuy5,000C$2.24C$11,184.00
12/3/2015Pierre LaurinDirectorSell259,125C$2.99C$774,913.31
11/17/2015Jonathan BoothInsiderBuy25,000C$2.21C$55,225.00
9/30/2015Kurt Stefan Victor ClulowDirectorBuy50,000C$1.43C$71,500.00
9/29/2015Kurt Stefan Victor ClulowDirectorBuy153,400C$1.42C$217,889.36
9/25/2015Raymond Manuel HakimDirectorBuy15,000C$1.69C$25,399.50
9/15/2015Andrew Trevor BishopDirectorBuy10,000C$1.81C$18,100.00
9/8/2015Simon Geoffrey BestDirectorBuy30,000C$1.95C$58,464.00
8/24/2015Nancy Orr-GaucherDirectorBuy2,800C$1.75C$4,900.00
8/21/2015Pierre LaurinDirectorBuy2,400C$1.83C$4,392.00
7/16/2015Simon Geoffrey BestDirectorBuy60,000C$2.43C$145,782.00
7/15/2015Patrick SartoreInsiderSell122,736C$2.30C$282,722.38
7/15/2015Steven J BurtonDirectorSell49,842C$2.30C$114,811.05
7/2/2015Kurt Stefan Victor ClulowDirectorBuy229,900C$2.32C$533,184.08
6/30/2015Kurt Stefan Victor ClulowDirectorBuy770,100C$2.26C$1,742,736.30
6/29/2015Kurt Stefan Victor ClulowDirectorBuy114,750C$2.10C$240,435.68
6/26/2015Kurt Stefan Victor ClulowDirectorBuy885,250C$2.12C$1,879,208.70
6/16/2015Patrick SartoreInsiderBuy2,300C$2.24C$5,152.00
6/12/2015Patrick SartoreInsiderBuy4,000C$2.28C$9,122.00
6/11/2015Louise M�NardDirectorBuy10,000C$2.35C$23,500.00
6/5/2015Raymond Manuel HakimDirectorBuy50,000C$2.45C$122,495.00
6/4/2015Paul MesburisDirectorSell115,593C$2.40C$277,423.20
5/22/2015Nancy Orr-GaucherDirectorSell9,787C$2.47C$24,173.89
4/9/2015Nancy Orr-GaucherDirectorSell9,657C$2.72C$26,267.04
4/7/2015Bruce PritchardInsiderBuy10,200C$2.74C$27,943.92
2/6/2015John Edward MoranDirectorBuy64,500C$1.51C$97,395.00
1/12/2015Patrick SartoreInsiderSell279,656C$1.87C$523,348.24
1/12/2015Pierre LaurinDirectorSell956,264C$1.87C$1,789,552.45
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ProMetic Life Sciences (TSE:PLI)
Latest Headlines for ProMetic Life Sciences (TSE:PLI)
Source:
DateHeadline
prnewswire.com logoPrometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and ... - PR Newswire (press release)
www.prnewswire.com - July 13 at 8:01 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Director Sells C$131,523.20 in Stock
www.americanbankingnews.com - July 11 at 5:30 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 5:30 PM
americanbankingnews.com logoScotiabank Cuts ProMetic Life Sciences Inc. (PLI) Price Target to C$4.00
www.americanbankingnews.com - July 7 at 2:06 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Price Target Lowered to C$4.50 at Canaccord Genuity
www.americanbankingnews.com - June 19 at 10:23 AM
reuters.com logoBRIEF-Prometic reports $53 mln bought deal offering
www.reuters.com - June 16 at 8:58 AM
prnewswire.com logoNew data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in ... - PR Newswire (press release)
www.prnewswire.com - June 12 at 7:50 AM
finance.yahoo.com logoNew data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in patients with diabetes and metabolic syndrome
finance.yahoo.com - June 12 at 7:50 AM
americanbankingnews.com logoInsider Buying: ProMetic Life Sciences Inc. (PLI) Insider Buys 7,000 Shares of Stock
www.americanbankingnews.com - June 1 at 4:50 PM
americanbankingnews.com logoMartin Leclerc Buys 8,950 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - May 26 at 10:35 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Earns "Outperform" Rating from Royal Bank of Canada
www.americanbankingnews.com - May 24 at 10:59 AM
prnewswire.com logoPrometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 - PR Newswire (press release)
www.prnewswire.com - May 24 at 10:04 AM
reuters.com logoBRIEF-Prometic presents new data on PBI-4050 and plasminogen
www.reuters.com - May 23 at 9:52 AM
finance.yahoo.com logoPrometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 International Conference
finance.yahoo.com - May 23 at 9:52 AM
americanbankingnews.com logoSimon Geoffrey Best Buys 10,000 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - May 19 at 4:24 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 19 at 10:07 AM
americanbankingnews.com logoNational Bank Financial Weighs in on ProMetic Life Sciences Inc.'s FY2017 Earnings (PLI)
www.americanbankingnews.com - May 19 at 8:04 AM
finance.yahoo.com logoPrometic Reports 2017 First Quarter Highlights and Financial Results
finance.yahoo.com - May 16 at 9:50 AM
reuters.com logoBRIEF-Prometic Life Sciences Inc plasminogen administration shown to reduce acute lung injury
www.reuters.com - May 9 at 11:07 AM
finance.yahoo.com logoPrometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference
finance.yahoo.com - May 8 at 12:01 PM
marketwatch.com logoPrometic Announces the Closing of the $25 Million Follow-On Financing From Structured Alpha LP, an Affiliate of ... - MarketWatch
www.marketwatch.com - April 28 at 8:21 AM
finance.yahoo.com logoPrometic Announces the Closing of the $25 Million Follow-On Financing From Structured Alpha LP, an Affiliate of Thomvest Asset Management Inc.
finance.yahoo.com - April 28 at 8:21 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 24 at 11:39 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - April 23 at 12:38 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Earns "Outperform" Rating from Scotiabank
www.americanbankingnews.com - April 22 at 10:52 PM
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks ProMetic Life Sciences, Concordia International, Theratechnologies ... - Yahoo Finance
finance.yahoo.com - April 21 at 8:57 AM
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks ProMetic Life Sciences, Concordia International, Theratechnologies, and Aurinia Pharmaceuticals
finance.yahoo.com - April 21 at 8:57 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Director Andrew Trevor Bishop Buys 10,000 Shares
www.americanbankingnews.com - April 20 at 2:32 PM
reuters.com logoBRIEF-Prometic PBI-4050 shown to reduce liver damage, fibrosis in induced obesity and metabolic syndrome mouse model
www.reuters.com - April 20 at 8:55 AM
finance.yahoo.com logoFDA confirms Prometic's PBI-4050 IPF clinical trial design
finance.yahoo.com - April 18 at 9:44 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Insider Bruce Pritchard Purchases 15,300 Shares
www.americanbankingnews.com - April 12 at 8:09 PM
americanbankingnews.com logoHybridan Llp Research Analysts Decrease Earnings Estimates for ProMetic Life Sciences Inc. (PLI)
www.americanbankingnews.com - April 7 at 8:43 PM
americanbankingnews.com logoFY2017 Earnings Estimate for ProMetic Life Sciences Inc. Issued By National Bank Financial (PLI)
www.americanbankingnews.com - April 5 at 3:04 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) PT Lowered to C$4.75
www.americanbankingnews.com - April 3 at 3:46 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) PT Set at C$4.50 by TD Securities
www.americanbankingnews.com - April 3 at 3:46 PM
americanbankingnews.com logoRoyal Bank of Canada Trims ProMetic Life Sciences Inc. (PLI) Target Price to C$4.00
www.americanbankingnews.com - April 3 at 1:16 PM
finance.yahoo.com logoEdited Transcript of PLI.TO earnings conference call or presentation 31-Mar-17 3:00pm GMT
finance.yahoo.com - April 1 at 11:09 AM
marketwatch.com logoPrometic Reports its 2016 Fourth Quarter and Year End Highlights ... - MarketWatch
www.marketwatch.com - March 31 at 8:39 AM
reuters.com logoBRIEF-Prometic Life Sciences Inc entered into a binding memorandum of terms with Shenzhen Royal Asset Management
www.reuters.com - March 30 at 7:32 PM
finance.yahoo.com logoPrometic and Shenzhen Royal Asset management (SRAM) to establish a joint venture to develop, manufacture …
finance.yahoo.com - March 30 at 7:32 PM
biz.yahoo.com logoQ4 2016 ProMetic Life Sciences Inc Earnings Release - After Market Close
biz.yahoo.com - March 30 at 7:32 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 12:59 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) to Release Earnings on Tuesday
www.americanbankingnews.com - March 27 at 7:50 AM
marketwatch.com logoPrometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP, an ... - MarketWatch
www.marketwatch.com - March 26 at 8:05 AM
finance.yahoo.com logoPrometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
finance.yahoo.com - March 24 at 8:20 AM
americanbankingnews.com logoRoyal Bank of Canada Lowers ProMetic Life Sciences Inc. (PLI) Price Target to C$4.25
www.americanbankingnews.com - March 22 at 2:07 PM
finance.yahoo.com logoUS FDA Grants Orphan Drug Designation to Prometic's PBI-4050 Drug for the Treatment of Alström Syndrome
finance.yahoo.com - March 3 at 8:39 AM
reuters.com logoBRIEF-Prometic says PBI-4050 shows encouraging efficacy in IPF study
www.reuters.com - February 22 at 9:19 AM
finance.yahoo.com logoIIROC Trading Halt - PLI
finance.yahoo.com - February 18 at 10:13 AM
finance.yahoo.com logoIIROC Trade Resumption - PLI
finance.yahoo.com - February 16 at 6:53 PM

Social

Chart

ProMetic Life Sciences (PLI) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff